Cardiorenal outcomes by indices of liver steatosis and fibrosis in individuals with type 2 diabetes and atherosclerotic cardiovascular disease: Analyses from VERTIS CV, a randomized trial of the sodium‐glucose cotransporter‐2 inhibitor ertugliflozin

To conduct a post hoc analysis to explore indices of hepatic steatosis/fibrosis and cardiorenal outcomes in the VERTIS CV study.

[1]  B. Zinman,et al.  Effects of empagliflozin on markers of liver steatosis and fibrosis and their relationship to cardiorenal outcomes , 2022, Diabetes, obesity & metabolism.

[2]  E. Halm,et al.  Nonalcoholic Fatty Liver Disease and Risk of Heart Failure Among Medicare Beneficiaries , 2021, Journal of the American Heart Association.

[3]  Z. Younossi,et al.  Causes of Death in Patients with Non-alcoholic Fatty Liver Disease (NAFLD), Alcoholic Liver Disease and Chronic Viral Hepatitis B and C. , 2021, Annals of hepatology.

[4]  Sang-Man Jin,et al.  The association of hepatic steatosis and fibrosis with heart failure and mortality , 2021, Cardiovascular Diabetology.

[5]  G. Salles,et al.  Prognostic impact of liver fibrosis and steatosis by transient elastography for cardiovascular and mortality outcomes in individuals with nonalcoholic fatty liver disease and type 2 diabetes: the Rio de Janeiro Cohort Study , 2021, Cardiovascular Diabetology.

[6]  C. Byrne,et al.  Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis. , 2021, The lancet. Gastroenterology & hepatology.

[7]  V. Wong,et al.  Defining comprehensive models of care for NAFLD , 2021, Nature Reviews Gastroenterology & Hepatology.

[8]  M. Ebert,et al.  Surrogate scores of advanced fibrosis in NAFLD/NASH do not predict mortality in patients with medium-to-high cardiovascular risk. , 2021, American Journal of Physiology - Gastrointestinal and Liver Physiology.

[9]  Yuan-Lin Guo,et al.  Liver fibrosis scores and coronary atherosclerosis: novel findings in patients with stable coronary artery disease , 2021, Hepatology International.

[10]  C. Cannon,et al.  Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial , 2021, Diabetologia.

[11]  C. Cannon,et al.  Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes , 2020, JAMA cardiology.

[12]  C. Cannon,et al.  Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. , 2020, The New England journal of medicine.

[13]  C. Valério,et al.  NAFLD as a continuum: from obesity to metabolic syndrome and diabetes , 2020, Diabetology & Metabolic Syndrome.

[14]  Hyejung Jung,et al.  Obesity and weight loss are inversely related to mortality and cardiovascular outcome in prediabetes and type 2 diabetes: data from the ORIGIN trial , 2020, European heart journal.

[15]  C. Byrne,et al.  NAFLD as a driver of chronic kidney disease. , 2020, Journal of hepatology.

[16]  A. Gastaldelli,et al.  Screening for non-alcoholic fatty liver disease in type 2 diabetes using non-invasive scores and association with diabetic complications , 2020, BMJ Open Diabetes Research & Care.

[17]  P. Galle,et al.  Impact of NAFLD on the Incidence of Cardiovascular Diseases in a Primary Care Population in Germany , 2019, Digestive Diseases and Sciences.

[18]  N. Sattar,et al.  Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million European adults , 2019, BMJ.

[19]  L. Henry,et al.  Mortality Related to Nonalcoholic Fatty Liver Disease Is Increasing in the United States , 2019, Hepatology communications.

[20]  P. Tandon,et al.  Impact of Implementing a “FIB‐4 First” Strategy on a Pathway for Patients With NAFLD Referred From Primary Care , 2019, Hepatology communications.

[21]  N. Chalasani,et al.  Nonalcoholic Fatty Liver Disease and the Heart: JACC State-of-the-Art Review. , 2019, Journal of the American College of Cardiology.

[22]  C. Cannon,et al.  Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS‐CV) , 2018, American heart journal.

[23]  R. Bai,et al.  Chronic heart failure in patients with nonalcoholic fatty liver disease: prevalence, clinical features, and relevance , 2018, The Journal of international medical research.

[24]  V. Wong,et al.  Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta‐analysis , 2017, Hepatology.

[25]  S. Bakker,et al.  Associations of the fatty liver and hepatic steatosis indices with risk of cardiovascular disease: Interrelationship with age. , 2017, Clinica chimica acta; international journal of clinical chemistry.

[26]  E. Bjornsson,et al.  Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. , 2015, Gastroenterology.

[27]  Mats Fredrikson,et al.  Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up , 2015, Hepatology.

[28]  W. Doehner.  Critical appraisal of the obesity paradox in cardiovascular disease: How to manage patients with overweight in heart failure? , 2014, Heart Failure Reviews.

[29]  T. Therneau,et al.  Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States , 2013, Hepatology.

[30]  K. Flegal,et al.  Association of All-Cause Mortality With Overweight and Obesity Using Standard Body Mass Index Categories , 2012 .

[31]  H. Kim,et al.  Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. , 2010, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[32]  J. Montaner,et al.  Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection , 2006, Hepatology.